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What does it take to develop one new
cancer drug?

•One billion dollars and 10-15 years
•Drug discovery (5000-10,000 compounds)
•Preclinical laboratory work (250 compounds)
•Clinical trials in humans
•FDA submission and approval

How have cancer drugs changed?
1970- 1990’s

•
•
•
•
•

Cytotoxic
Non-specific
Intravenous toxins
Highly toxic

DNA damaging

2000 and beyond

•
•
•
•
•

Cytostatic

More selective
Oral/IV biologics
Well-tolerated

Targets the tumor
and tumor
environment

Why do we
need patient
participation
in clinical
trials?

Recently FDA approved oncology
compounds
• Everolimus
• Bendamustine
• Sunitinib
• Sorafenib
• Nilotinib
• Ixabepilone
• Temsirolimus
• Lapatinib
• Velcade
• Imatinib

•
•
•
•
•
•
•
•
•
•

Vorinostat
Rituxan
Panitumumab
Lenalomide
Dasatinib
Decitabine
Cetuximab
Rituximab
Trastuzumab
Bevacizumab

•
•
•
•
•
•
•
•

Denosumab
Pazopanib
Sipuleucel-T
Eribulin
Ofatumumab
Ipilimumab
Cabazitaxel
Crizotinib

FDA approved oncology drugs 2012-2013
• Obinutuzumab
• Pertuzumab
• Nab-paclitaxel
• Afatinib
• Trametinib
• Dabrafenib
• Abiraterone
• Cabozanitinib
• Vandetanib

•
•
•
•
•
•
•
•
•
•
•

Omacetaxine
Regorafenib
Bosutinib
Enzalutamide
Ziv-aflibercept
Carfilzomib
Vismodegib
Axitinib
Ruxolitinib
Brentuximab
Vemurafenib

Barriers to Clinical Trial Enrollment
• Access
• Education
– Patient perceptions
• “guinea pig”
• “I don’t want a placebo”
• “Will my insurance cover this?”
– MD perceptions
• Too time intensive
• Too much paperwork

• $$$$$

ONLY ~ 10% of
all adult
cancer
patients
participate in
clinical trials!

Pancreatic Cancer

Resection

Locally advanced
Metastatic

ADJUVANT
THERAPY

•
•

RTOG 0848
HyperAcute
Vaccine (CLOSED)

•
•

PALLIATIVE THERAPY

•

Gemcitabine/cisplatin +
birinapant

Gemcitabine/Nabpaclitaxel/XRT
FOLFIRINOX and
HyperAcute Vaccine

Adjuvant Phase III Trial-RTOG 0848

Principle Investigator: Adam Berger, MD

HyperAcute®-Pancreas immunotherapy
Adjuvant therapy (Gemcitabine alone or with 5-FU
chemoradiation) with or without HyperAcute®-Pancreas
(algenpantucel-L) immunotherapy in subjects who have
undergone surgical resection

Principal Investigator: Harish Lavu, MD

HyperAcute® Technology

α(1,3)GT gene
Selected human pancreatic
cancer cell lines

Selected human lung
cancer cell lines

α(1,3)GT gene introduced into human cancer
cells
using viruses

Locally Advanced Unresectable
Pancreatic Adenocarcinoma

Gemcitabine and Nab-Paclitaxel
as a Promising Combination
• Gemcitabine and Nab-Paclitaxel IV
weekly x 3 with 1 week off

Patients with metastatic
pancreas cancer receiving this
doublet did better than the
group receiving gemcitabine
alone.

vonHoff et al ASCO, 2013

Upcoming Gem/Paclitaxel Trial for Locally
Advanced Pancreas Cancer
Cycle 1

Cycle 2

(4 wks)

(4 wks)

Gem

▐▐▐ ▄

▐▐▐ ▄

Nab-paclitaxel

▐▐▐ ▄

▐▐▐ ▄

Tumor response
evaluation/
rule out
metastatic
disease

CRT*

Cycle 3

Cycle 4

(4 wks)

(4 wks)

▐▐▐ ▄

▐▐▐ ▄

▐▐▐ ▄

▐▐▐ ▄

(2 wks)

▐▐

Tumor response/
resectability
evaluation every two
cycles

CRT
30 Gy
3Gy/fx

Principal Investigator: Voichita Bar-Ad, MD

FOLFIRINOX as a Promising Regimen
5Fluorouracil
Oxaliplatin
Leucovorin
Irinotecan

IV every 2 weeks
Patients with metastatic
pancreas cancer did better
than the group receiving
gemcitabine alone.
NEJM 364 (19): 1817-1825, 2011

Open Trial of FOLFIRINOX With
or Without HyperAcute®Pancreas Immunotherapy Trial
for Locally Advanced Pancreas
Cancer

Study Schema

Principal Investigator: Harish Lavu, MD

Metastatic Pancreas Cancer

Birinapant
•

•
•

Programmed cell death is
called apoptosis.
Cancer cells circumvent
apoptosis and continue to grow.
TL32711 or birinapant,
antagonizes the cancer cells’
inhibitors of apoptosis and can
make the chemotherapy work
better at killing cancer cells.

Gemcitabine/Cisplatin + TL 327811 (Birinapant)
Pancreas Cancer
Table 1b: Dose escalation scheme of TL32711 in combination with gemcitabine plus cisplatin (Part A2) (each
cycle is 21 days)

Dose Level

TL32711 (iv)

-A1

17 mg/m2
once weekly x 2

A1

22 mg/m2
once weekly x 2

A2

26 mg/m2
once weekly x 2

A3

35 mg/m2
once weekly x 2

Gemcitabine (iv) once
weekly x 2 weeks (Day
1 and 8)

Cisplatin (iv) once
every 3 weeks
(Day 1)

1000 mg/m2

75 mg/m2

Principal Investigator: Nancy Lewis, MD

“Enrollment in a
clinical trial is the
best management
for patients with
cancer”
National Comprehensive
Cancer Network Guidelines
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